LAVA Therapeutics NV (LVTX) Stock Analysis

LAVA Therapeutics NV (LVTX) is a publicly traded company in the HEALTHCARE sector. It trades at $1.74. This page summarizes the public market data, fundamentals, and frequently asked questions for LVTX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

About LAVA Therapeutics NV

LAVA Therapeutics NV is a pioneering biotechnology company dedicated to transforming cancer treatment through its innovative gamma-delta bispecific T-cell activators (gamma-delta bsTCE). Based in Utrecht, the Netherlands, LAVA boasts a promising development pipeline that utilizes its proprietary technology to create next-generation therapies aimed at effectively targeting solid tumors and hematologic malignancies. With a strong commitment to enhancing immune responses against cancer, LAVA The...

GNG Research Analysis

GNG Research scores LAVA Therapeutics NV (LVTX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for LVTX.

Frequently Asked Questions

Does LVTX pay dividends?

LAVA Therapeutics NV (LVTX) does not currently pay a regular dividend.